Search NEL Online

Case Reports 2014; 35(3): 175-178 PubMed PMID: 24977963 Citation  Keywords:  Administration, Oral, Adult, Female, Hormone Antagonists:administration & dosage, Humans, Leiomyoma:complications, Menstruation Disturbances:drug therapy, Middle Aged, Norpregnadienes:administration & dosage, Receptors, Progesterone:metabolism, Treatment .   

OBJECTIVES: Uterine fibroids are the most common benign tumors in women of reproductive age. Evidence suggest that ovarian steroid hormones, in particular, progesterone play a major role in promoting leiomyoma development and growth. For the last years there was an extensive research on selective progesterone receptor modulators and their use in therapy. Ulipristal acetate (UPA) is one of these modulators. The aim of this paper is to evaluate efficacy and safety of oral ulipristal acetate for the treatment in women with symptomatic uterine fibroids.

METHODS: The study group comprised five patients with uterine fibroids. All patients received 5 mg of ulipristal acetate per day for three months.

RESULTS: The total volume of fibroids decreased by 33-68%. In all patients during the administration of UPA significant reduction of menstrual bleeding was observed. Increase of endometrial thickness without clinical significance was observed in two patients. No significant side-effects were observed during the treatment period.

CONCLUSIONS: 1) The volume offibroids decreased from 33 to 68%. 2) The UPA administration effectively controlled excessive bleeding. 3) Treatment with UPA may modify the scope of the surgery. 4) UPA is a well-tolerated drug....

Read abstract  Full text PDF

Case Reports 2008; 29(6): 857-866 PubMed PMID: 19112416 Citation  Keywords:  Antineoplastic Combined Chemotherapy Protocols:therapeutic use, Biological Therapy:methods, Breast Neoplasms:therapy, Carcinoma, Ductal, Breast:therapy, Complementary Therapies, Female, Hormone Antagonists:administration & dosage, Humans, Middle Aged, Neo.   

: In this case presentation, a woman with breast carcinoma who chose to try Prof. L. DiBella's biological therapy (MDB), was found, after seven months, to have a 50% reduction in objective measures of her carcinoma and was totally cured after 14 months. The patient's recovery extended to bilateral axillary adenopathies, and took place without the toxicity normally associated with cancer treatment. MDB entails the use of anti-proliferative molecules such as somatostatine, prolactin, and estrogen inhibitors, along with differentiating and apoptotic molecules such as melatonin, retinoids, vitamins C, D3, and E, calcium, and amino-sugars, combined with minimal doses of chemotherapy. The hemato-chemical exams showed no damage, with a progressive reduction of prolactin, estradiol, IGF1, and maintenance of low levels of GH. The achievement of objective results, without toxicity, in this case, proves the effectiveness of this therapy and confirms the positive results already published on the use of MDB for Low-Grade NHL, and pulmonary carcinomas in the 3rd and 4th stages. MDB, without the need for either hospitalization or day hospitalization, without toxicity, and without even minimally reducing the patient's daily work routine, allowed the patient to avoid surgical trauma and the significant collateral effects of chemo- and radiotherapy. Timely use of MDB as the first line therapy, in a patient which had not been debilitated by the mutagenic, toxic, and immuno-depressive effects of chemo- and radiotherapy, contributed greatly to the final outcome. We feel it is useful to highlight this case in an effort to stimulate interest and further study into the oncological potential of MDB biological and receptor therapy....

Read abstract  Full text PDF